ArticleNature communications2024

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.

Michael P Cooreman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.